Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK rearrange CD274 over exp |
Therapy | Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK rearrange CD274 over exp | lung adenocarcinoma | predicted - sensitive | Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium | Case Reports/Case Series | Actionable | In a clinical case study, a patient with ALK-rearranged lung adenocarcinoma with high CD274 (PD-L1) expression (TPS>=50%) who progressed on 3 prior ALK inhibitors experienced a rapid and ongoing clinical improvement with the combination therapy of Tecentriq (atezolizumab), Avastin (bevacizumab), Paraplatin (carboplatin), and Alimta (Pemetrexed Disodium), achieving decreased lung lesion size, complete metabolic response of liver lesions, and partial response of bone lesions (PMID: 34336591). | 34336591 |
PubMed Id | Reference Title | Details |
---|---|---|
(34336591) | A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma. | Full reference... |